CPT2 and colorectal cancer: Another study on colorectal cancer showed that downregulated CPT2 is equally capable of promoting colorectal cancer stemness and oxaliplatin resistance by disrupting the balance of intracellular redox homeostasis, promoting ROS production and activating the downstream Wnt/β-catenin signaling pathway, and inducing glycolytic metabolism [129].